Vaxcyte (PCVX) AGM 2026 summary

Opening remarks and agenda

• Meeting called to order by the Chairman, with board members and key executives present.

• Inspector of Election and representatives from Deloitte & Touche in attendance.

• Voting procedures and eligibility clarified, with polls opened for voting.

• Notice of meeting and affidavit of mailing incorporated into the minutes.

Shareholder proposals

• Election of three Class III directors to serve until the 2029 Annual Meeting.

• Ratification of Deloitte & Touche LLP as independent auditor for fiscal year ending December 31, 2026.

• Advisory vote on executive compensation as disclosed in the proxy statement.

Overview of voting outcomes

• Quorum established with 95.13% of shares represented.

• All board-recommended proposals passed according to preliminary voting results.

• Results to be disclosed in a Form 8-K filing with the SEC.